Targeting Siglec-E facilitates tumor vaccine-induced antitumor immunity in renal carcinoma

Targeting Siglec-E facilitates tumor vaccine-induced antitumor immunity in renal carcinoma

Background Siglec-E is an immune checkpoint inhibitory molecule. Expression of Siglec-E on the immune cells has been shown to promote tumor regression. This study aimed to develop an adenovirus (Ad) vaccine targeting Siglec-E and carbonic anhydrase IX (CAIX) (Ad-Siglec-E/CAIX) and to evaluate its po...

Full description

Saved in:
Bibliographic Details
Main Authors: Yuchen Zhang, Junnian Zheng, Li Sun, Guangya Zhao, Yingxiang Shao, Bowen Lu, Jiage Ding, Yanyan Zheng, Renjin Chen, Dafei Chai, Jiawei Wang, Zichun Zhang, Xiaohui Xie
Format: Article
Language:English
Published: BMJ Publishing Group 2025-01-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/13/1/e010521.full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://jitc.bmj.com/content/13/1/e010521.full

Similar Items